Rasburicase

DB00049

biotech approved investigational

Deskripsi

Rasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 18 hours
Volume Distribusi * 110 to 127 mL/kg [pediatric patients] * 75.8 to 138 mL/kg [adult patients]
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

53 Data
Prilocaine The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Prilocaine.
Dapsone The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Rasburicase.
Aminosalicylic acid The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Aminosalicylic acid.
Butalbital The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Butalbital.
Phenytoin The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Phenytoin.
Lidocaine The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Lidocaine.
Ropivacaine The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Ropivacaine.
Bupivacaine The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Bupivacaine.
Valproic acid The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Valproic acid.
Acetaminophen The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Acetaminophen.
Nitroprusside The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Nitroprusside.
Sulfadiazine The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Sulfadiazine.
Nitric Oxide The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Nitric Oxide.
Quinine The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Quinine.
Celecoxib The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Celecoxib.
Flutamide The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Flutamide.
Cyclophosphamide The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Cyclophosphamide.
Chloroquine The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Chloroquine.
Nitrofurantoin The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Nitrofurantoin.
Procaine The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Procaine.
Nitroglycerin The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Nitroglycerin.
Sulfasalazine The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Sulfasalazine.
Isosorbide dinitrate The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Isosorbide dinitrate.
Sulfapyridine The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Sulfapyridine.
Mepivacaine The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Mepivacaine.
Hydroxyurea The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Hydroxyurea.
Sulfamethoxazole The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Sulfamethoxazole.
Isosorbide mononitrate The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Isosorbide mononitrate.
Benzocaine The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Benzocaine.
Primaquine The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Primaquine.
Phenobarbital The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Phenobarbital.
Ifosfamide The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Ifosfamide.
Zopiclone The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Zopiclone.
Metoclopramide The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Metoclopramide.
Antipyrine The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Antipyrine.
Phenazopyridine The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Phenazopyridine.
Amyl Nitrite The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Amyl Nitrite.
Nitrous oxide The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Nitrous oxide.
Isometheptene The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Isometheptene.
Articaine The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Articaine.
Tetracaine The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Tetracaine.
Methyclothiazide The therapeutic efficacy of Rasburicase can be decreased when used in combination with Methyclothiazide.
Bendroflumethiazide The therapeutic efficacy of Rasburicase can be decreased when used in combination with Bendroflumethiazide.
Benzthiazide The therapeutic efficacy of Rasburicase can be decreased when used in combination with Benzthiazide.
Cyclothiazide The therapeutic efficacy of Rasburicase can be decreased when used in combination with Cyclothiazide.
Hydroflumethiazide The therapeutic efficacy of Rasburicase can be decreased when used in combination with Hydroflumethiazide.
Chlorothiazide The therapeutic efficacy of Rasburicase can be decreased when used in combination with Chlorothiazide.
Hydrochlorothiazide The therapeutic efficacy of Rasburicase can be decreased when used in combination with Hydrochlorothiazide.
Trichlormethiazide The therapeutic efficacy of Rasburicase can be decreased when used in combination with Trichlormethiazide.
Polythiazide The therapeutic efficacy of Rasburicase can be decreased when used in combination with Polythiazide.
Mebutizide The therapeutic efficacy of Rasburicase can be decreased when used in combination with Mebutizide.
Cyclopenthiazide The therapeutic efficacy of Rasburicase can be decreased when used in combination with Cyclopenthiazide.
Buthiazide The therapeutic efficacy of Rasburicase can be decreased when used in combination with Buthiazide.

Target Protein

Uric acid

Referensi & Sumber

Synthesis reference: Roy Eugene Snoke, Hugh Arthur Risley, Charles Thomas Goodhue, "Production of uricase from micrococcus luteus." U.S. Patent US4062731, issued May, 1974.
Artikel (PubMed)
  • PMID: 20445229
    Collings I, Watier Y, Giffard M, Dagogo S, Kahn R, Bonnete F, Wright JP, Fitch AN, Margiolaki I: Polymorphism of microcrystalline urate oxidase from Aspergillus flavus. Acta Crystallogr D Biol Crystallogr. 2010 May;66(Pt 5):539-48. doi: 10.1107/S0907444910005354. Epub 2010 Apr 21.
  • PMID: 20394650
    Giraldez M, Puto K: A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults. Eur J Haematol. 2010 Aug;85(2):177-9. doi: 10.1111/j.1600-0609.2010.01457.x. Epub 2010 Apr 12.

Contoh Produk & Brand

Produk: 6 • International brands: 0
Produk
  • Elitek
    Injection, powder, lyophilized, for solution; Kit • 1.5 mg/1mL • Intravenous • US • Approved
  • Elitek
    Injection, powder, lyophilized, for solution; Kit • 7.5 mg/5mL • Intravenous • US • Approved
  • Fasturtec
    Powder, for solution • 1.5 mg / vial • Intravenous • Canada • Approved
  • Fasturtec
    Powder, for solution • 7.5 mg / vial • Intravenous • Canada • Approved
  • Fasturtec
    Injection, powder, for solution • 1.5 mg/ml • Intravenous • EU • Approved
  • Fasturtec
    Injection, powder, for solution • 1.5 mg/ml • Intravenous • EU • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul